Released May 9, 2013, after the close
10-Q filed May 13, 2013, 43 days after period end · 0001019687-13-001786
Q1 2013 · 10-Q
Revenue$6.12M$6.12M +0.8% vs Q1 2012+3.1% vs Q4 2012
Net Income-$369.00K-$369.00K N/M vs Q1 2012N/M vs Q4 2012
EPS Diluted-$0.01-$0.01 N/M vs Q1 2012N/M vs Q4 2012
Operating Income-$366,000N/M
Operating Cash Flow$166,000−34.9%
Free Cash Flowderived$43,000N/M
Margins · derived
Operating margin-6.0%+10.5 pt vs Q1 2012
Net margin-6.0%+11.2 pt vs Q1 2012
What the release said
The release
Same quarter
| Metric | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|
| Revenue | $6.12M | $6.07M | $6.00M |
| Net Income | -$369.00K | -$1.05M | -$559.00K |
| EPS Diluted | -$0.01 | -$0.02 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR